Transtec 52.5 Micrograms/H Transdermal Patch
SUMMARY OF PRODUCT CHARACTERISTICS
1 NAME OF THE MEDICINAL PRODUCT
TRANSTEC® 52.5 micrograms/h transdermal patch
2 QUALITATIVE AND QUANTITATIVE COMPOSITION
TRANSTEC® 52.5 micrograms/h transdermal patch:
One transdermal patch contains 30 mg buprenorphine.
Area containing the active substance: 37.5 cm2
Nominal release rate: 52.5 micrograms of buprenorphine per hour (over a period of 96 hours).
For the full list of excipients, see section 6.1.
3 PHARMACEUTICAL FORM
Transdermal patch
Skin coloured transdermal patch with rounded corners marked:
TRANSTEC® 52.5 pg/h, buprenorphinum 30 mg
4 CLINICAL PARTICULARS
4.1 Therapeutic indications
Moderate to severe cancer pain and severe pain which does not respond to non-opioid analgesics.
TRANSTEC® is not suitable for the treatment of acute pain.
4.2 Posology and method of administration
Posology
Patients over 18 years of age
The TRANSTEC® dosage should be adapted to the condition of the individual patient (pain intensity, suffering, individual reaction). The lowest possible dosage providing adequate pain relief should be given. Three transdermal patch strengths are available to provide such adaptive treatment: TRANSTEC® 35 micrograms/h, TRANSTEC® 52.5 micrograms/h and TRANSTEC® 70 micrograms/h.
Initial dose selection: patients who have previously not received any analgesics should start with the lowest transdermal patch strength (TRANSTEC® 35 micrograms/h). Patients previously given a WHO step-I analgesic (non-opioid) or a step-II analgesic (weak opioid) should also begin with TRANSTEC® 35 micrograms/h. According to the WHO recommendations, the administration of a non-opioid analgesic can be continued, depending on the patient's overall medical condition.
When switching from a step-III analgesic (strong opioid) to TRANSTEC® and choosing the initial transdermal patch strength, the nature of the previous medication, administration and the mean daily dose should be taken into account in order to avoid the recurrence of pain. In general it is advisable to titrate the dose individually, starting with the lowest transdermal patch strength (TRANSTEC® 35 micrograms/h). Clinical experience has shown that patients who were previously treated with higher daily dosages of a strong opioid (in the dimension of approximately 120 mg oral morphine) may start the therapy with the next higher transdermal patch strength (see also section 5.1).
To allow for individual dose adaptation in an adequate time period sufficient supplementary immediate release analgesics should be made available during dose titration.
The necessary strength of TRANSTEC® must be adapted to the requirements of the individual patient and checked at regular intervals.
After application of the first TRANSTEC® transdermal patch the buprenorphine serum concentrations rise slowly both in patients who have been treated previously with analgesics and in those who have not. Therefore initially, there is unlikely to be a rapid onset of effect. Consequently, a first evaluation of the analgesic effect should only be made after 24 hours.
The previous analgesic medication (with the exception of transdermal opioids) should be given in the same dose during the first 12 hours after switching to TRANSTEC® and appropriate rescue medication on demand in the following 12 hours.
Dose titration and maintenance therapy
TRANSTEC® should be replaced after 96 hours (4 days) at the latest. For convenience of use, the transdermal patch can be changed twice a week at regular intervals, e.g. always on Monday morning and Thursday evening. The dose should be titrated individually until analgesic efficacy is attained. If analgesia is insufficient at the end of the initial application period, the dose may be increased, either by applying more than one transdermal patch of the same strength or by switching to the next transdermal patch strength. At the same time no more than two transdermal patches regardless of the strength should be applied.
Before application of the next TRANSTEC® strength the amount of total opioids administered in addition to the previous transdermal patch should be taken into consideration, i.e. the total amount of opioids required, and the dosage adjusted accordingly. Patients requiring a supplementary analgesic (e.g. for breakthrough pain) during maintenance therapy may take for example one to two 0.2 mg buprenorphine sublingual tablets every 24 hours in addition to the transdermal patch. If the regular addition of 0.4 - 0.6 mg sublingual buprenorphine is necessary, the next strength should be used.
Paediatric population
As TRANSTEC® has not been studied in patients under 18 years of age, the use of the medicinal product in patients below this age is not recommended.
Elderly patients
No dosage adjustment of TRANSTEC® is required for elderly patients.
Patients with renal insufficiency
Since the pharmacokinetics of buprenorphine is not altered during the course of renal failure, its use in patients with renal insufficiency, including dialysis patients, is possible.
Patients with hepatic insufficiency
Buprenorphine is metabolised in the liver. The intensity and duration of its action may be affected in patients with impaired liver function. Therefore patients with liver insufficiency should be carefully monitored during treatment with TRANSTEC®.
Method of application
TRANSTEC® should be applied to non-irritated, clean skin on a non-hairy flat surface, but not to any parts of the skin with large scars. Preferable sites on the upper body are: upper back or below the collar-bone on the chest. Any remaining hairs should be cut off with a pair of scissors (not shaved). If the site of application requires cleansing, this should be done with water. Soap or any other cleansing agents should not be used. Skin preparations that might affect adhesion of the transdermal patch to the area selected for application of TRANSTEC® should be avoided.
The skin must be completely dry before application. TRANSTEC® is to be applied immediately after removal from the sachet. Following removal of the release liner, the transdermal patch should be pressed firmly in place with the palm of the hand for approximately 30 seconds. The transdermal patch will not be affected when bathing, showering or swimming. However, it should not be exposed to excessive heat (e.g. sauna, infrared-radiation).
TRANSTEC® should be worn continuously for up to 4 days. After removal of the previous transdermal patch a new TRANSTEC® transdermal patch should be applied to a different skin site. At least one week should elapse before a new transdermal patch is applied to the same area of skin.
Duration of administration
TRANSTEC® should under no circumstances be administered for longer than absolutely necessary. If long-term pain treatment with TRANSTEC® is necessary in view of the nature and severity of the illness, then careful and regular monitoring should be carried out (if necessary with breaks in treatment) to establish whether and to what extent further treatment is necessary.
Discontinuation of Transtec®
After removal of TRANSTEC® buprenorphine serum concentrations decrease gradually and thus the analgesic effect is maintained for a certain amount of time. This should be considered when therapy with TRANSTEC® is to be followed by other opioids. As a general rule, a subsequent opioid should not be administered within 24 hours after removal of TRANSTEC®. For the time being only limited information is available on the starting dose of other opioids administered after discontinuation of TRANSTEC®.
4.3 Contraindications
TRANSTEC® is contraindicated in:
- hypersensitivity to the active substance or to any of the excipients listed in section 6.1.
- opioid-dependent patients and for narcotic withdrawal treatment
- conditions in which the respiratory centre and function are severely impaired or may become so
patients who are receiving MAO inhibitors or have taken them within the last two weeks (see section 4.5)
patients suffering from myasthenia gravis
patients suffering from delirium tremens.
pregnancy (see section 4.6)
4.4 Special warnings and precautions for use
TRANSTEC® must only be used with particular caution in acute alcohol intoxication, convulsive disorders, in patients with head injury, shock, a reduced level of consciousness of uncertain origin, increased intracranial pressure without the possibility of ventilation.
Buprenorphine occasionally causes respiratory depression. Therefore care should be taken when treating patients with impaired respiratory function or patients receiving medicinal products which can cause respiratory depression.
Buprenorphine has a substantially lower dependence liability than pure opioid agonists. In healthy volunteer and patient studies with TRANSTEC®, withdrawal reactions have not been observed. However, after long-term use of TRANSTEC® withdrawal symptoms, similar to those occurring during opiate withdrawal, cannot be entirely excluded (see section 4.8). These symptoms are: agitation, anxiety, nervousness, insomnia, hyperkinesia, tremor and gastrointestinal disorders.
In patients abusing opioids, substitution with buprenorphine may prevent withdrawal symptoms. This has resulted in some abuse of buprenorphine and caution should be exercised when prescribing it to patients suspected of having drug abuse problems.
Buprenorphine is metabolised in the liver. The intensity and duration of effect may be altered in patients with liver function disorders. Therefore such patients should be carefully monitored during TRANSTEC® treatment.
Athletes should be aware that this medicine may cause a positive reaction to sports doping control tests.
Paediatric population
As TRANSTEC® has not been studied in patients under 18 years of age, the use of the medicinal product in patients below this age is not recommended.
Patients with fever / external heat
Fever and the presence of heat may increase the permeability of the skin.
Theoretically in such situations buprenorphine serum concentrations may be raised during TRANSTEC® treatment. Therefore on treatment with TRANSTEC®, attention should be paid to the increased possibility of opioid reactions in febrile patients or those with increased skin temperature due to other causes.
4.5 Interaction with other medicinal products and other forms of interaction
On administration of MAO inhibitors in the last 14 days prior to the administration of the opioid pethidine life-threatening interactions have been observed affecting the central nervous system and respiratory and cardiovascular function. The same interactions between MAO inhibitors and TRANSTEC® cannot be ruled out (see section 4.3).
When TRANSTEC® is applied together with other opioids, anaesthetics, hypnotics, sedatives, antidepressants, neuroleptics, and in general, medicinal products that depress respiration and the central nervous system, the CNS effects may be intensified. This applies also to alcohol.
Administered together with inhibitors or inducers of CYP 3A4 the efficacy of TRANSTEC® may be intensified (inhibitors) or weakened (inducers).
4.6 Fertility, pregnancy and lactation
Pregnancy
There are no adequate data from the use of TRANSTEC® in pregnant women. Studies in animals have shown reproductive toxicity (see section 5.3). The potential risk for humans is unknown.
Towards the end of pregnancy high doses of buprenorphine may induce respiratory depression in the neonate even after a short period of administration. Long-term administration of buprenorphine during the last three months of pregnancy may cause a withdrawal syndrome in the neonate.
Therefore TRANSTEC® is contraindicated during pregnancy.
Breast-feeding
Buprenorphine is excreted in human milk. In rats, buprenorphine has been found to inhibit lactation.
TRANSTEC® should not be used during lactation.
Fertility
An effect of buprenorphine on fertility in animals is not known (see section 5.3).
4.7 Effects on ability to drive and use machines
Transtec® has major influence on the ability to drive and use machines.
Even when used according to instructions, TRANSTEC® may affect the patient’s reactions to such an extent that road safety and the ability to operate machinery may be impaired.
This applies particularly at the beginning of treatment, at any change of dosage and when TRANSTEC® is used in conjunction with other centrally acting substances including alcohol, tranquillisers, sedatives and hypnotics.
Patients who are affected (e.g. feeling dizzy or drowsy or experience blurred or double vision) should not drive or use machines while using TRANSTEC® and for at least 24 hours after the patch has been removed.
Patients stabilized on a specific dosage will not necessarily be restricted if the above mentioned symptoms are not present.
Additional information for UK only
This medicine can impair cognitive function and can affect a patient’s ability to drive safely. This class of medicine is in the list of drugs included in regulations under 5a of the Road Traffic Act 1988. When prescribing this medicine, patients should be told:
• The medicine is likely to affect your ability to drive.
• Do not drive until you know how the medicine affects you.
• It is an offence to drive while you have this medicine in your body over a specified limit unless you have a defence (called the ‘statutory defence’).
• This defence applies when:
o The medicine has been prescribed to treat a medical or dental problem; and
o You have taken it according to the instructions given by the prescriber and in the information provided with the medicine.
• Please note that it is still an offence to drive if you are unfit because of the medicine (i.e. your ability to drive is being affected).
Details regarding a new driving offence concerning driving after drugs have been taken in the UK may be found here:
https://www.gov.uk/drug-driving-law
4.8 Undesirable effects
The following adverse reactions were reported after administration of TRANSTEC® in clinical studies and from postmarketing surveillance.
The frequencies are given as follows:
Very common (>1/10)
Common (>1/100, <1/10)
Uncommon (>1/1,000, <1/100)
Rare (>1/10,000, <1/1,000)
Very rare (<1/10,000)
Not known (cannot be estimated from the available data)
a) The most commonly reported systemic adverse reactions were nausea and vomiting. The most commonly reported local adverse reactions were erythema and pruritus.
b)
Immune system disorders
Very rare: serious allergic reactions*
Metabolism and nutrition disorders
Rare: appetite lost
Psychiatric disorders
Uncommon: confusion, sleep disorder, restlessness
Rare: psychotomimetic effects (e.g. hallucinations, anxiety,
nightmares), decreased libido
Very rare: dependence, mood swings
Nervous system disorders
Common: dizziness, headache
Uncommon: sedation, somnolence
|
Rare: Very rare: Eye disorders |
concentration impaired, speech disorder, numbness, dysequilibrium, paraesthesia (e.g. pricking or burning skin sensation) muscle fasciculation, parageusia |
|
Rare: |
visual disturbance, blurring of vision, eyelid oedema |
|
Very rare: Ear and labyrinth disorders |
miosis |
|
Very rare: Cardiac/Vascular disorders |
ear pain |
|
Uncommon: |
circulatory disorders (such as hypotension or, rarely, even circulatory collapse) |
Rare: hot flushes
Respiratory, thoracic and mediastinal disorders
Common: dyspnoea
|
Rare: Very rare: Gastrointestinal disorders |
respiratory depression hyperventilation, hiccups |
|
Very common: |
nausea |
|
Common: Uncommon: |
vomiting, constipation dry mouth |
|
Rare: |
pyrosis |
Very rare: retching
Skin and subcutaneous tissue disorders
Very common: erythema, pruritus
|
Common: Uncommon: |
exanthema, diaphoresis rash |
|
Rare: |
urticaria |
Very rare: pustules, vesicles
Renal and urinary disorders
Uncommon: urinary retention, micturition disorders
Reproductive system and breast disorders
Rare: decreased erection
General disorders and administration site conditions
Common: oedema, tiredness
|
Uncommon: |
weariness |
|
Rare: Very rare: |
withdrawal symptoms*, administration site reactions thoracic pain |
* see section c)
c) In some cases delayed allergic reactions occurred with marked signs of inflammation. In such cases treatment with TRANSTEC® should be terminated.
Buprenorphine has a low risk of dependence. After discontinuation of TRANSTEC®, withdrawal symptoms are unlikely. This is due to the very slow dissociation of buprenorphine from the opiate receptors and to the gradual decrease of buprenorphine serum concentrations (usually over a period of 30 hours after removal of the last transdermal patch). However, after long-term use of TRANSTEC® withdrawal symptoms, similar to those occurring during opiate withdrawal, cannot be entirely excluded. These symptoms include: agitation, anxiety, nervousness, insomnia, hyperkinesia, tremor and gastrointestinal disorders.
Reporting of suspected adverse reactions
Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via
United Kingdom
Yellow Card Scheme
Website: www.mhra.gov .uk/yellowcard
4.9 Overdose
Buprenorphine has a wide safety margin. Due to the rate-controlled delivery of small amounts of buprenorphine into the blood circulation high or toxic buprenorphine concentrations in the blood are unlikely. The maximum serum concentration of buprenorphine after the application of the TRANSTEC® 70 micrograms/h transdermal patch is about six times less than after the intravenous administration of the therapeutic dose of 0.3 mg buprenorphine.
Symptoms
In principal, on overdose with buprenorphine, symptoms similar to those of other centrally acting analgesics (opioids) are to be expected. These are: respiratory depression, sedation, somnolence, nausea, vomiting, cardiovascular collapse, and marked miosis.
Treatment
General emergency measures apply. Keep the airway open (aspiration!), maintain respiration and circulation depending on the symptoms. Naloxone has a limited impact on the respiratory depressant effect of buprenorphine. High doses are needed given either as repeated boluses or infusion (for example starting with a bolus administration of 1-2 mg intravenously. Having attained an adequate antagonistic effect, administration by infusion is recommended to maintain constant naloxone plasma levels). Therefore, adequate ventilation should be established.
5 PHARMACOLOGICAL PROPERTIES
5.1 Pharmacodynamic properties
Pharmacotherapeutic group: Opioids, Oripavine derivatives. ATC code: N02AE01.
Buprenorphine is a strong opioid with agonistic activity at the mu-opioid receptor and antagonistic activity at the kappa-opioid receptor. Buprenorphine appears to have the general characteristics of morphine, but has its own specific pharmacology and clinical attributes.
In addition, numerous factors, e.g. indication and clinical setting, route of administration and the interindividual variability, have an impact on analgesia and therefore have to be considered when comparing analgesics.
In daily clinical practice different opioids are ranked by a relative potency, although this is to be considered a simplification.
The relative potency of buprenorphine in different application forms and in different clinical settings has been described in literature as follows:
• Morphine p.o. : BUP i.m. as 1 : 67 - 150 (single dose; acute pain model)
• Morphine p.o. : BUP s.l. as 1 : 60 - 100 (single dose, acute pain model; multiple dose , chronic pain, cancer pain)
• Morphine p.o. : BUP TTS as 1 : 75 - 115 (multiple dose, chronic pain)
5.2 Pharmacokinetic properties
a) General characteristics of the active substance
Buprenorphine has a plasma protein binding of about 96%.
Buprenorphine is metabolised in the liver to A-dealkylbuprenorphine (norbupren-orphine) and to glucuronide conjugated metabolites. 2/3 of the active substance is eliminated unchanged in the faeces and V3 eliminated as conjugates of unchanged or dealkylated buprenorphine via the urinary system. There is evidence of enterohepatic recirculation.
Studies in non-pregnant and pregnant rats have shown that buprenorphine passes the blood-brain and placental barriers. Concentrations in the brain (which contained only unchanged buprenorphine) after parenteral administration were 2-3 times higher than after oral administration. After intramuscular or oral administration buprenorphine apparently accumulates in the foetal gastrointestinal lumen - presumably due to biliary excretion, as enterohepatic circulation has not fully developed.
b) Characteristics of TRANSTEC® in healthy volunteers
After the application of TRANSTEC®, buprenorphine is absorbed through the skin. The continuous delivery of buprenorphine into the systemic circulation is by controlled release from the adhesive polymer-based matrix system.
After the initial application of TRANSTEC® the plasma concentrations of buprenorphine gradually increase, and after 12-24 h the plasma concentrations reach the minimum effective concentration of 100 pg/ml. From the studies performed with the TRANSTEC® 35 micrograms/h in healthy volunteers, an average Cmax of 200 to 300 pg/ml and an average tmax of 60-80 h were determined. In one volunteer study, TRANSTEC® 35 micrograms/h and TRANSTEC® 70 micrograms/h were applied in a cross-over design. From this study, dose proportionality for the different strengths was demonstrated.
After removal of TRANSTEC® the plasma concentrations of buprenorphine steadily decrease and are eliminated with a half-life of approx. 30 hours (range 22 - 36). Due to the continuous absorption of buprenorphine from the depot in the skin elimination is slower than after intravenous administration.
5.3 Preclinical safety data
Standard toxicological studies have not shown evidence of any particular potential risks for humans. In tests with repeated doses of buprenorphine in rats the increase in body weight was reduced.
Studies on fertility and general reproductive capacity of rats showed no detrimental effects. Studies in rats and rabbits revealed signs of fetotoxicity and increased postimplantation loss.
Studies in rats showed diminished intra-uterine growth, delays in the development of certain neurological functions and high peri/post natal mortality in the neonates after treatment of the dams during gestation or lactation. There is evidence that complicated delivery and reduced lactation contributed to these effects. There was no evidence of embryotoxicity including teratogenicity in rats or rabbits.
In vitro and in vivo examinations on the mutagenic potential of buprenorphine did not indicate any clinically relevant effects.
In long-term studies in rats and mice there was no evidence of any carcinogenic potential relevant for humans.
Toxicological data available did not indicate a sensitising potential of the additives of the transdermal patches.
6. PHARMACEUTICAL PARTICULARS
6.1 List of excipients
Adhesive matrix (containing buprenorphine): [(Z)-octadec-9-en-1-yl] oleate, povidone K90, 4-oxopentanic acid, poly[acrylic acid-co-butylacrylate-co-(2-ethylhexyl)acrylate-co-vinylacetate] (5:15:75:5), cross-linked
Adhesive matrix (without buprenorphine): poly[acrylic acid-co-butylacrylate-co-(2-ethylhexyl)acrylate-co-vinylacetate] (5:15:75:5), cross-linked
Separating foil between the adhesive matrices with and without buprenorphine: poly(ethyleneterephthalate) - foil
Backing layer: poly(ethyleneterephthalate) - tissue
Release liner (on the front covering the adhesive matrix containing buprenorphine) (to be removed before applying the patch): poly(ethyleneterephthalate) - foil, siliconised, coated on one side with aluminium
Incompatibilities
6.2
Not applicable.
6.3 Shelf life
3 years.
6.4 Special precautions for storage
This medicinal product does not require any special storage conditions.
6.5 Nature and contents of container
Type of container:
Sealed sachet, composed of identical top and bottom layers of heat-sealable laminate, comprising (from outside to inside) paper, low density polyethylene, aluminium and poly(acrylic acid-co-ethylene) (= surlyn).
Pack sizes:
Packs containing 3, 4, 5, 6, 8, 10, 11, 12, 16, 18, 20 or 24 individually sealed transdermal patches.
Not all pack sizes may be marketed.
6.6 Special precautions for disposal
Any unused medicinal product or waste material should be disposed of in accordance with local requirements.
7. MARKETING AUTHORISATION HOLDER
Grunenthal GmbH Zieglerstrasse 6 52078 Aachen Germany
8. MARKETING AUTHORISATION NUMBER
PL 04539/0015
9. DATE OF FIRST AUTHORISATION/RENEWAL OF THE AUTHORISATION
27 February 2002
10
DATE OF REVISION OF THE TEXT
25/09/2014